

Agenus To Host BOT/BAL Program Update at ESMO 2023

10/5/2023

LEXINGTON, Mass.--(BUSINESS WIRE)-- Agenesis Inc. (Nasdaq: AGEN), a leader in developing novel immunological agents to treat various cancers, today announced that the Company will host a corporate event to discuss advancements in its botensilimab/balstilimab (BOT/BAL) program at the upcoming European Society for Medical Oncology (ESMO) Conference on Sunday, October 22, 2023. Agenesis will provide updates from the ongoing BOT/BAL clinical program, including in neoadjuvant colorectal cancer and pancreatic cancer. A live webcast of the event will be available.

Speakers include:

- Alexander Eggermont, M.D., Ph.D., University Medical Center, Utrecht, Princess Maxima Center for Pediatric Oncology, Comprehensive Cancer Center
- Marwan Fakih, M.D., City of Hope
- Manuel Hidalgo, M.D., Ph.D., Weill Cornell Medicine
- Pashtoon Kasi, M.D., M.S., Weill Cornell Medicine
- Breelyn Wilky, M.D., University of Colorado Medicine
- Steven O'Day, M.D., Chief Medical Officer, Agenesis
- Todd Yancey, M.D., Senior Advisor, Agenesis

Event Details

Date: Sunday, October 22, 2023

Time: 19:00 – 21:00 CEST (1:00 p.m. – 3:00 p.m. EDT)

To register for the webcast, please click [here](#).

About Agenus

Agenus is a leading immuno-oncology company targeting cancer and infectious diseases with a comprehensive pipeline of immunological agents. The company's mission is to expand patient populations benefiting from cancer immunotherapy through combination approaches, using a broad repertoire of antibody therapeutics, adoptive cell therapies (through MiNK Therapeutics) and adjuvants (through SaponiQx). Agenus is headquartered in Lexington, MA. For more information, visit www.agenusbio.com or [@agenus_bio](https://twitter.com/agenus_bio). Information that may be important to investors will be routinely posted on our website and Twitter.

Forward Looking Statements

This press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws, including statements regarding a Agenus's corporate event at ESMO and related presentation about its botensilimab programs and any other statements containing the words "may," "believes," "expects," "anticipates," "hopes," "intends," "plans," "forecasts," "estimates," "will," "establish," "potential," "superiority," "best in class," and similar expressions are intended to identify forward-looking statements. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include, among others, the factors described under the Risk Factors section of our most recent Quarterly Report on Form 10-Q or Annual Report on Form 10-K filed with the Securities and Exchange Commission. Agenus cautions investors not to place considerable reliance on the forward-looking statements contained in this release. These statements speak only as of the date of this press release, and Agenus undertakes no obligation to update or revise the statements, other than to the extent required by law. All forward-looking statements are expressly qualified in their entirety by this cautionary statement.

Investors

917-362-1370

investor@agenusbio.com

Media

781-674-4784

communications@agenusbio.com

Source: Agenus Inc.